Achiko AG (SIX: ACHI.SW) is developing disruptive diagnostic solutions that puts people first. Invented by Dr Michael Edel, the company’s flagship product is a fast, friendly, affordable and accurate Covid-19 test with a companion app. The test and companion app were launched in Indonesia in mid-2021 and AptameX™ received the CE Mark in the European Union in May 2022. Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX™ and companion health apps via its digital mobile health technology division, Teman Sehat™. The AptameX™ DNA aptamer tests can be rapidly chemically synthesised, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX™ and Teman Sehat™, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field. Headquartered in Zurich, Achiko has offices in Jakarta and Singapore.
